Financhill
Sell
27

CTSO Quote, Financials, Valuation and Earnings

Last price:
$0.94
Seasonality move :
-0.04%
Day range:
$0.87 - $0.94
52-week range:
$0.70 - $1.61
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.44x
P/B ratio:
5.30x
Volume:
1.3M
Avg. volume:
116K
1-year change:
14.72%
Market cap:
$58.9M
Revenue:
$35.6M
EPS (TTM):
-$0.36

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CTSO
CytoSorbents
$9M -$0.07 13.09% -41.38% $5.00
DCTH
Delcath Systems
$16.8M $0.03 436.11% -93.78% $22.50
EXAS
Exact Sciences
$688.6M -$0.10 9.99% -84.17% $68.41
ILMN
Illumina
$1B $0.94 -3.25% 430.2% $115.55
STIM
Neuronetics
$29.1M -$0.12 66.89% -56.79% $6.83
STRR
Star Equity Holdings
$16.4M -$0.25 79.32% -70.59% $10.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CTSO
CytoSorbents
$0.94 $5.00 $58.9M -- $0.00 0% 1.44x
DCTH
Delcath Systems
$12.40 $22.50 $414.2M -- $0.00 0% 9.80x
EXAS
Exact Sciences
$51.55 $68.41 $9.7B -- $0.00 0% 3.38x
ILMN
Illumina
$77.88 $115.55 $12.3B -- $0.00 0% 2.84x
STIM
Neuronetics
$4.58 $6.83 $301.4M -- $0.00 0% 1.94x
STRR
Star Equity Holdings
$2.23 $10.00 $7.1M 0.75x $0.00 0% 0.13x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CTSO
CytoSorbents
51.51% 1.160 16.8% 1.46x
DCTH
Delcath Systems
-- 2.997 -- 10.46x
EXAS
Exact Sciences
49.21% 0.148 28.45% 2.12x
ILMN
Illumina
45.6% 0.950 9.36% 1.26x
STIM
Neuronetics
66.56% -3.580 58.84% 1.37x
STRR
Star Equity Holdings
17.24% -0.314 43.09% 1.26x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CTSO
CytoSorbents
$4.5M -$4.4M -70.49% -103.21% -20.27% -$2.8M
DCTH
Delcath Systems
$13M $3M -97.08% -117.89% 68.93% -$1.2M
EXAS
Exact Sciences
$500.5M -$89.8M -19.08% -35.57% -13.04% -$365K
ILMN
Illumina
$728M $193M -22.97% -35.09% 19.2% $335M
STIM
Neuronetics
$14.9M -$11.5M -54.36% -178.53% -52.12% -$8.7M
STRR
Star Equity Holdings
$4.4M $3.6M -15.36% -17.45% 20.95% -$3.9M

CytoSorbents vs. Competitors

  • Which has Higher Returns CTSO or DCTH?

    Delcath Systems has a net margin of -27.1% compared to CytoSorbents's net margin of -22.5%. CytoSorbents's return on equity of -103.21% beat Delcath Systems's return on equity of -117.89%.

    Company Gross Margin Earnings Per Share Invested Capital
    CTSO
    CytoSorbents
    52.3% -$0.04 $26.8M
    DCTH
    Delcath Systems
    85.92% -$0.11 $68.7M
  • What do Analysts Say About CTSO or DCTH?

    CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 431.92%. On the other hand Delcath Systems has an analysts' consensus of $22.50 which suggests that it could grow by 81.45%. Given that CytoSorbents has higher upside potential than Delcath Systems, analysts believe CytoSorbents is more attractive than Delcath Systems.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTSO
    CytoSorbents
    1 1 0
    DCTH
    Delcath Systems
    4 0 0
  • Is CTSO or DCTH More Risky?

    CytoSorbents has a beta of 1.171, which suggesting that the stock is 17.12% more volatile than S&P 500. In comparison Delcath Systems has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.805%.

  • Which is a Better Dividend Stock CTSO or DCTH?

    CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTSO or DCTH?

    CytoSorbents quarterly revenues are $8.6M, which are smaller than Delcath Systems quarterly revenues of $15.1M. CytoSorbents's net income of -$2.3M is higher than Delcath Systems's net income of -$3.4M. Notably, CytoSorbents's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.44x versus 9.80x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTSO
    CytoSorbents
    1.44x -- $8.6M -$2.3M
    DCTH
    Delcath Systems
    9.80x -- $15.1M -$3.4M
  • Which has Higher Returns CTSO or EXAS?

    Exact Sciences has a net margin of -27.1% compared to CytoSorbents's net margin of -14.32%. CytoSorbents's return on equity of -103.21% beat Exact Sciences's return on equity of -35.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    CTSO
    CytoSorbents
    52.3% -$0.04 $26.8M
    EXAS
    Exact Sciences
    70.82% -$0.54 $4.7B
  • What do Analysts Say About CTSO or EXAS?

    CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 431.92%. On the other hand Exact Sciences has an analysts' consensus of $68.41 which suggests that it could grow by 32.71%. Given that CytoSorbents has higher upside potential than Exact Sciences, analysts believe CytoSorbents is more attractive than Exact Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTSO
    CytoSorbents
    1 1 0
    EXAS
    Exact Sciences
    17 3 0
  • Is CTSO or EXAS More Risky?

    CytoSorbents has a beta of 1.171, which suggesting that the stock is 17.12% more volatile than S&P 500. In comparison Exact Sciences has a beta of 0.920, suggesting its less volatile than the S&P 500 by 7.968%.

  • Which is a Better Dividend Stock CTSO or EXAS?

    CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTSO or EXAS?

    CytoSorbents quarterly revenues are $8.6M, which are smaller than Exact Sciences quarterly revenues of $706.8M. CytoSorbents's net income of -$2.3M is higher than Exact Sciences's net income of -$101.2M. Notably, CytoSorbents's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.44x versus 3.38x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTSO
    CytoSorbents
    1.44x -- $8.6M -$2.3M
    EXAS
    Exact Sciences
    3.38x -- $706.8M -$101.2M
  • Which has Higher Returns CTSO or ILMN?

    Illumina has a net margin of -27.1% compared to CytoSorbents's net margin of 16.94%. CytoSorbents's return on equity of -103.21% beat Illumina's return on equity of -35.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    CTSO
    CytoSorbents
    52.3% -$0.04 $26.8M
    ILMN
    Illumina
    65.94% $1.17 $4.4B
  • What do Analysts Say About CTSO or ILMN?

    CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 431.92%. On the other hand Illumina has an analysts' consensus of $115.55 which suggests that it could grow by 48.37%. Given that CytoSorbents has higher upside potential than Illumina, analysts believe CytoSorbents is more attractive than Illumina.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTSO
    CytoSorbents
    1 1 0
    ILMN
    Illumina
    7 11 0
  • Is CTSO or ILMN More Risky?

    CytoSorbents has a beta of 1.171, which suggesting that the stock is 17.12% more volatile than S&P 500. In comparison Illumina has a beta of 1.349, suggesting its more volatile than the S&P 500 by 34.945%.

  • Which is a Better Dividend Stock CTSO or ILMN?

    CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTSO or ILMN?

    CytoSorbents quarterly revenues are $8.6M, which are smaller than Illumina quarterly revenues of $1.1B. CytoSorbents's net income of -$2.3M is lower than Illumina's net income of $187M. Notably, CytoSorbents's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.44x versus 2.84x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTSO
    CytoSorbents
    1.44x -- $8.6M -$2.3M
    ILMN
    Illumina
    2.84x -- $1.1B $187M
  • Which has Higher Returns CTSO or STIM?

    Neuronetics has a net margin of -27.1% compared to CytoSorbents's net margin of -56.29%. CytoSorbents's return on equity of -103.21% beat Neuronetics's return on equity of -178.53%.

    Company Gross Margin Earnings Per Share Invested Capital
    CTSO
    CytoSorbents
    52.3% -$0.04 $26.8M
    STIM
    Neuronetics
    66.21% -$0.33 $87M
  • What do Analysts Say About CTSO or STIM?

    CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 431.92%. On the other hand Neuronetics has an analysts' consensus of $6.83 which suggests that it could grow by 49.2%. Given that CytoSorbents has higher upside potential than Neuronetics, analysts believe CytoSorbents is more attractive than Neuronetics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTSO
    CytoSorbents
    1 1 0
    STIM
    Neuronetics
    1 1 0
  • Is CTSO or STIM More Risky?

    CytoSorbents has a beta of 1.171, which suggesting that the stock is 17.12% more volatile than S&P 500. In comparison Neuronetics has a beta of 1.919, suggesting its more volatile than the S&P 500 by 91.876%.

  • Which is a Better Dividend Stock CTSO or STIM?

    CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neuronetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Neuronetics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CTSO or STIM?

    CytoSorbents quarterly revenues are $8.6M, which are smaller than Neuronetics quarterly revenues of $22.5M. CytoSorbents's net income of -$2.3M is higher than Neuronetics's net income of -$12.7M. Notably, CytoSorbents's price-to-earnings ratio is -- while Neuronetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.44x versus 1.94x for Neuronetics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTSO
    CytoSorbents
    1.44x -- $8.6M -$2.3M
    STIM
    Neuronetics
    1.94x -- $22.5M -$12.7M
  • Which has Higher Returns CTSO or STRR?

    Star Equity Holdings has a net margin of -27.1% compared to CytoSorbents's net margin of -14.37%. CytoSorbents's return on equity of -103.21% beat Star Equity Holdings's return on equity of -17.45%.

    Company Gross Margin Earnings Per Share Invested Capital
    CTSO
    CytoSorbents
    52.3% -$0.04 $26.8M
    STRR
    Star Equity Holdings
    26.02% -$0.94 $65.7M
  • What do Analysts Say About CTSO or STRR?

    CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 431.92%. On the other hand Star Equity Holdings has an analysts' consensus of $10.00 which suggests that it could grow by 348.43%. Given that CytoSorbents has higher upside potential than Star Equity Holdings, analysts believe CytoSorbents is more attractive than Star Equity Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    CTSO
    CytoSorbents
    1 1 0
    STRR
    Star Equity Holdings
    1 0 0
  • Is CTSO or STRR More Risky?

    CytoSorbents has a beta of 1.171, which suggesting that the stock is 17.12% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.871, suggesting its less volatile than the S&P 500 by 12.92%.

  • Which is a Better Dividend Stock CTSO or STRR?

    CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

  • Which has Better Financial Ratios CTSO or STRR?

    CytoSorbents quarterly revenues are $8.6M, which are smaller than Star Equity Holdings quarterly revenues of $17.1M. CytoSorbents's net income of -$2.3M is higher than Star Equity Holdings's net income of -$2.5M. Notably, CytoSorbents's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.44x versus 0.13x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CTSO
    CytoSorbents
    1.44x -- $8.6M -$2.3M
    STRR
    Star Equity Holdings
    0.13x 0.75x $17.1M -$2.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Salesforce Stock Drop After a Strong Quarter?
Why Did Salesforce Stock Drop After a Strong Quarter?

Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…

Is Adobe Stock a Bargain With AI Tools Driving Growth?
Is Adobe Stock a Bargain With AI Tools Driving Growth?

The share price of American computer software company Adobe (NASDAQ:ADBE)…

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Stock Ideas

Buy
71
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Sell
4
CABO alert for May 3

Cable One [CABO] is down 41.98% over the past day.

Buy
55
PDEX alert for May 3

Pro-Dex [PDEX] is down 32.02% over the past day.

Buy
91
TRUP alert for May 3

Trupanion [TRUP] is up 23.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock